NLN. A. Lushnikova

N. A. Lushnikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


N. A. Lushnikova has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ewing’s sarcoma of the ureter: a case report

    by Z. A. Yurmazov, N. A. Lushnikova, E. A. Usynin, N. V. Bezgodova, E. G. Grigoriev

    Ewing’s sarcoma is a highly aggressive malignant tumor that often affects the bones. Genitourinary organs are an exceedingly rare location of the Ewing’s sarcoma. There are still no widely accepted treatment protocols for such patients. We report a rare case of Ewing’s sarcoma of the ureter in a 68-year-old man who was admitted to the Cancer Research Institute, Tomsk National Research Medical Center. He was suspected of having a bladder tumor. After completing his treatment course which included surgery and adjuvant chemotherapy, the patient demonstrated no signs of local recurrence or metastasis for a long time.

  • Open Access

    Clinical experience of using the radium-223 in patients with bone metastasis of castration-resistant prostate cancer

    by Z. A. Yurmazov, E. A. Usynin, A. A. Medvedeva, A. A. Polyakov, N. A. Lushnikova, V. I. Chernov, L. V. Spirina

    Background. Prostate cancer is one of the actual problems of modern oncology. The incidence of prostate cancer is steadily increasing despite of popularization of screening and early diagnostics. It is worth to highlight separately the castration-resistant prostate cancer which develops on the average 2 years after surgical or medicinal castration. For the patients with metastatic castration-resistant prostate cancer (mCRPC) the main purpose of treatment is increasing of overall survival while maintaining the quality of life. Currently there are several treatment options for mCRPC: chemotherapy, inhibitors of androgen receptor pathway,systemic alfa-radiotherapy, PARP-inhibitorsfor homologousrecombination DNA repair deficiency. Using of several sequential lines of mCRPC therapy leads to maintaining the patients’ quality of life and increasing its duration. Systemic alfa-radiotherapy is using since 2013 – the first is radium-223 which was approved by Food and Drug Administration according the results of the phase III trial ALSYMPCA. In Russian Federation radium-223 was approved in 2016.Objective: to evaluate the efficiency and safety oftherapy with radium-223 as well as pain response at patients with mCRPC.Materials and methods. 67 patients were included in this analysis who received radium-223 therapy at Scientific Research Institute of Tomsk National Research Medical Center of Russian Academy of Sciences and Tomsk Regional Oncology Dispensary.Results and conclusion. Radium-223 has demonstrated its efficiency for mCRPC patients with good safety profile and positive pain response and maintaining the QoL.


  • Open Access

    USE OF 177Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER

    by A. A. Medvedeva, V. I. Chernov, E. A. Usynin, R. V. Zelchan, O. D. Bragina, N. A. Lushnikova

    Purpose of the study: to present current data regarding challenges in treatment of castration-resistant prostate cancer (CRPC) and the relationship between CRPC and the expression of prostate-specific membrane antigen (psma).Material and Methods. The search for relevant sources was carried out in the Pubmed, elibrary, Medline databases. The review included 43 publications, most of which were published over the past 5 years.Results. Currently, prostate cancer (PC) is one of the most common cancers in men. Moreover, over time, most patients develop resistance to therapy, which significantly worsens the prognosis of the disease. Psma is one of the molecular markers of prostate cancer; a number of studies have demonstrated a direct correlation between the level of psma expression and the tumor grade, stage and aggressiveness. Numerous studies indicate that psma represents an excellent target for radionuclide therapy of prostate cancer. 68Ga or 18F-psma Pet/Ct is the most common method for diagnosing PC. It should be noted that modern trends in the development of nuclear medicine are closely related to theranostics; therefore, the creation of highly specific theranostic pairs for diagnosis and subsequent therapy of malignant tumors is of great significance. The data obtained indicate that 177lu demonstrates the most optimal radiation and physical characteristics for therapeutic radionuclides, while psma-617 is one of the most studied ligands for radionuclide therapy.Conclusion. Currently, there are several studies covering radionuclide therapy with various psmacompounds labeled with 177lu. Radionuclide therapy with 177lu-psma has been shown to be recommended for patients with metastatic CRPC, who have no benefits from alternative therapies or have contraindications to them.


  • Open Access

    Capabilities of preoperative targeted therapy in treatment of bone metastases in renal cancer

    by Z. A. Yurmazov, Надежда Андреевна Лушникова, L. V. Spirina, E. A. Usynin, E. M. Slonimskaya, I. I. Anisenya, A. V. Bogoutdinova

    The study objective is to evaluate the effectiveness of preoperative targeted therapy, spectrum and rate of adverse events, as well as quality of life in patients with bone metastases of renal cell carcinoma.Materials and methods. The study was conducted at the Research Institute of Oncology, Tomsk Medical Research Center between 2014 and 2018. The study included 34 patients with bone metastases of renal cell carcinoma who received preoperative targeted therapy with pazopanib for 8 weeks. All patients underwent surgical treatment of both the primary tumor and bone metastases.Results and conclusion. It was shown that preoperative targeted therapy is characterized by a high rate of clinical response and satisfactory tolerability. In some cases, preoperative targeted therapy improves the conditions for surgical treatment of metastatic bone lesions, decreases intraoperative blood loss, decreases the volume and duration of surgical intervention, which, in turn, allows to preserve bigger range of motion in the affected bone segment and improve patients’ quality of life.